10-Q: Burzynski Research Institute Reports Q1 2024 Results Amidst Ongoing Clinical Hold

Burzynski Research Institute reported a net loss of $371,332 for the first quarter of 2024, with operations primarily funded by Dr. Burzynski's contributions.

Summary

• Burzynski Research Institute, Inc. reported a net loss of $371,332 for the three months ended May 31, 2024, compared to a net loss of $287,405 for the same period in 2023.
• The company's research and development expenses increased to $226,088 from $182,114 year-over-year, due to increased facility, equipment, and personnel costs.
• General and administrative expenses also rose to $145,244 from $105,291, driven by higher legal and professional fees and increased regulatory reporting requirements.
• The company's operations are entirely funded by contributions from Dr. Burzynski, who is also the President, Chairman of the Board, and owner of approximately 81% of the outstanding common stock.
• The company's clinical trials for Antineoplaston drugs are currently under a full clinical hold by the FDA, preventing the enrollment of new patients.
• As of May 31, 2024, the company had a net deferred tax asset of $0, which includes a valuation allowance of $185,807.
• The company has net operating loss carryforwards of $473,902 expiring between 2026 and 2038, and $208,022 that will carryforward indefinitely.
• The company's cash and cash equivalents decreased from $1,310 to $297 during the quarter.

Sentiment

Score: 2

Explanation: The document reveals significant financial losses, a full clinical hold by the FDA, and a heavy reliance on a single funding source, indicating a very negative outlook for the company.

Positives

• The company has a new license agreement with Dr. Burzynski for exclusive rights to Antineoplastons in the US and Canada.
• The company has net operating loss carryforwards that can be used to offset future taxable income.
• The company has a research funding agreement with Dr. Burzynski that is expected to continue to renew annually.

Negatives

• The company is experiencing increased losses year-over-year.
• The company's clinical trials are under a full clinical hold by the FDA.
• The company is entirely dependent on funding from Dr. Burzynski's medical practice.
• The company has a working capital deficit and an accumulated deficit.
• The company has not generated significant revenues since its inception.
• The company's cash and cash equivalents have significantly decreased.

Risks

• The company's dependence on Dr. Burzynski's funding poses a significant risk to its operations.
• The full clinical hold by the FDA prevents the enrollment of new patients and the progress of clinical trials.
• There is no assurance that the company will ever achieve positive operating cash flow.
• The company may be required to seek additional capital through equity or debt financing, which may not be available on acceptable terms.
• The company is subject to potential claims by patients and other potential claimants.
• The company's ability to utilize net operating loss carryforwards depends on its ability to generate adequate future taxable income.

Future Outlook

The company anticipates spending approximately $900,000 during the remaining three quarters of the fiscal year ending February 28, 2025, and expects Dr. Burzynski to continue funding research and FDA-related costs, but there is no assurance of this.

Management Comments

• Management believes that the financial statements contain all adjustments necessary for a fair presentation of financial position.
• Management intends to comply fully with all FDA regulations.
• Management concluded that the company's disclosure controls and procedures are effective in timely alerting them to material information.

Industry Context

The company operates in the pharmaceutical research and development sector, specifically focusing on cancer treatments. The ongoing clinical hold and dependence on a single funding source are significant challenges in this industry, where regulatory approvals and financial stability are crucial for success.

Comparison to Industry Standards

• The company's lack of revenue and reliance on a single funding source is atypical compared to established pharmaceutical companies, which typically have diversified revenue streams and funding sources.
• The ongoing clinical hold is a significant deviation from industry norms, where companies strive to maintain positive relationships with regulatory bodies and progress through clinical trials.
• Companies like Amgen, Genentech, and Pfizer, which are leaders in the pharmaceutical industry, have diverse product portfolios, robust revenue streams, and established regulatory compliance processes, contrasting with Burzynski's current situation.
• The company's financial metrics, such as the net loss and lack of revenue, are significantly worse than industry benchmarks for companies at a similar stage of development.

Related Party Transactions

• The company is entirely dependent on funding from Dr. Burzynski, who is also the President, Chairman of the Board, and owner of approximately 81% of the outstanding common stock.
• Dr. Burzynski has funded the capital and operational needs of the company through his medical practice since inception.
• Dr. Burzynski provides the company laboratory and research space as needed to conduct the company's research activities.
• Dr. Burzynski pays the full amount of the company's monthly and annual budget of expenses for the operation of the company.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and dependence on a single funding source.
• Employees' job security is at risk due to the company's financial instability and dependence on Dr. Burzynski's funding.
• Patients are impacted by the full clinical hold, which prevents them from enrolling in clinical trials.
• The company's suppliers and creditors face risk due to the company's financial instability.

Next Steps

• The company needs to resolve the issues with the FDA to lift the full clinical hold on its trials.
• The company needs to secure additional funding to continue operations if Dr. Burzynski's funding ceases.
• The company needs to explore options for generating revenue to reduce its dependence on Dr. Burzynski's funding.

Key Dates

Keywords

Antineoplastons, clinical trials, FDA, research and development, clinical hold, cancer treatment, Burzynski Research Institute, financial results, net loss, funding